NCT06649331 2026-03-17Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerFudan UniversityPhase 2 Recruiting160 enrolled
NCT04129996 2022-01-11A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Fudan UniversityPhase 2 Unknown46 enrolled